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Editorial Comment
Factors Influencing
Myocardial Preservation After
Recombinant Tissue Plasminogen
Activator (rt-PA) in Acute
Myocardial Infarction*
CHARLES E. RACKLEY, MD, FACC,
LOWELL F. SATLER, MD, FACC
Washington. D.C.
The report by Topol and coworkers in this issue of the
Journal (I) presents further confirmatory evidence for the
benefits of early administration of recombinant tissue plas-
minogen activator (rt-PA) to patients with acute myocardial
infarction. The investigators found that the earlier admin-
istration of the thrombolytic agent in the emergency room
of the primary hospital produced superior results to admin-
istration of rt-PA during transportation to or ultimately at
the tertiary hospital. The benefits from early administration
included increased patency of the infarct-related coronary
artery, a reduction in hospital mortality and improved left
ventricular function. In this study, although the mortality
generally tended to be lower with early administration of
rt-PA, it was not statistically different from the mortality
of patients who received rt-PA later, after transportation to
the tertiary hospital. Twenty-one to 26% of all patients in
the study experienced recurrent angina, and 60 to 63%
underwent coronary angioplasty in the tertiary hospital.
This clinical study further emphasizes the important de-
terminants of myocardial salvage in the early treatment of
acute myocardial infarction. The following factors should
be considered in reducing infarct size and salvaging isch-
emic myocardium with thrombolytic therapy in acute myo-
cardial infarction: I) duration of ischemia; 2) collateral ves-
sels; 3) metabolic support; 4) residual stenosis; and5) definitive
therapy.
To achieve reperfusion within 3 hours after the onset of
symptoms of acute infarction, the thrombolytic agent has
to be administered before cardiac catheterization. The in-
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vestigators mentionthat <20% of the hospitals in this coun-
try currently have cardiac catheterization laboratories. Even
when cardiac catheterization is available, at least I or 2
hours' delay is introduced with the preparation for cathe-
terization before administration of thrombolytic therapy.
Therefore, successfuladministration of a thrombolytic agent
within the first 3 hours of infarction requires an accurate
diagnosis, intravenous access and a readily available throm-
bolytic agent. The clinical history and initial electrocardio-
gram remain the critical tools for early diagnosis, and Topol
et al.(l) note that myocardial infarction did not necessarily
evolve in all patients. Physicians must be alerted to con-
ditions such as aortic dissection, which can mimic the pain
of infarction and induce myocardial ischemia if underlying
coronary disease is also present (2).
Rogers et al. (3) earlier demonstrated that residual func-
tion after thrombolysis was influenced by the presence of
collateral vessels at the time of acute infarction. Collateral
flow around the occluded coronary artery can minimize the
temporary ischemia as well as diminish the insult of reper-
fusion injury.
Metabolic support of the acutely reperfused myocar-
dium. The potential damage of reperfusion to an ischemic
myocardium has been attributed to catecholamines, fatty
acids and oxygen toxicityboth experimentallyand clinically
(4). Althoughmetabolic support in the modeof cardioplegic
solution during cardiac surgery has been used for several
years, application of theseprinciplesto thrombolytictherapy
in acute myocardial infarction has not received widespread
clinical attention. Increasedavailabilityof glucose has been
recognized for many years to support the mechanical and
electrical stability of experimentally induced myocardial
ischemia. Positron emission tomography (PET) scanning in
patients with myocardial ischemia has confirmed the in-
creased uptake of glucose and diminished fatty acid metab-
olism in areasof reducedcoronaryblood flow (5,6). Clinical
studieswitha metabolic solutioncontainingglucose-insulin-
potassium have suggested improvement in hemodynamics,
arrhythmias, infarct size and mortality (7). Furthermore,
recent studies (8) with glucose-insulin-potassium combined
with streptokinase in acute infarction demonstrated pres-
ervation of segmental and global ventricular function com-
pared with streptokinase alone. Metabolic support during
reperfusion requiresadditional research in substrates, amino
acidsand pharmacologic agents that could support anaerobic
metabolism and minimize the harmful effects of catechol-
amines and oxygen.
Residual coronary stenosis and reocclusion. Clinical
and pathologic observations have confirmedthat myocardial
infarction usually results from a thrombus superimposedon
a high grade stenosis in an epicardialcoronary vessel. Satler
et al. (9) recentlyreported that after successful thrombolytic
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reperfusion 85% of patients demonstrate > 70% stenosis in
the infarct related vessel. Therefore, residualstenosis should
be expected after successful thrombolytic therapy. and the
disturbingly high reocclusion rate and recurrent ischemia
have testified to the impaired coronary flow after successful
thrombolysis. The incidence of recurrent ischemia, reoc-
c1usionand subsequent myocardial infarction is significantly
infl uenced by the degree of residual stenosis and reduced
coronary flow. Despite these clinical problems, evidence
for salvaged myocardium after successful thrombolysis has
been provided by ischemic pain induced with balloon oc-
clusion during coronary angioplasty and also by enhanced
myocardial contractibility with infusion of isoproterenol
(10,11).
Efforts to slow the atheromatous process. The present
study also demonstrates that coronary angioplasty can be
successfully performed in the majority of patients after suc-
cessful thrombolytic therapy. Long-term managementof the
patient after successful restoration of coronary blood flow
must be considered during the acute hospitalization because
angioplasty and bypass surgery can optimally be performed
during the same hospitalization. Even though sufficient
coronary flow may be rendered by mechanical means after
thrombolytic treatment for the acute infarction, an important
future consideration is the progression of the underlying
atheromatous process. A recent study by Satler et al. (12)
revealed in patients catheterized I year after angioplasty for
acute myocardial infarction that the restenosis rate in the
infarct-related vessel was approximately 30% and the native
coronary vessels exhibited a 50% incidence of progressive
atheromatous disease (1 2). Pharmacologic efforts must be
directed not only at stabilization of the infarct-related vessel,
but also at retardation of the atheromatous lesion in the
remainingcoronaryartery tree. Thus, the approaching avail-
ability of effective cholesterol-lowering agents should be
contemplated during the period of recovery after successful
thrombolytic therapy.
Conclusions. Administration of thrombolytic agents in
the community hospital appears to be feasible and superior
to administration after the costly delay of transportation to
a tertiary hospital. Future clinical objectives should include
rapid access to an electrocardiographic diagnosis by tele-
phone such as that made possible with the cardio-beeper
developed by Pratt et al. (1 3). Potential intramuscular
administration of rt-PA has already been shown feasible
in experimental animals by Sobel et al. (1 4). Finally, met-
abolic support of the acutely reperfused myocardium must
be expanded, and long-term efforts to reduce progression
of the atheromatous process must be included in the ag-
gressive approach of thrombolytic therapy in acute myo-
cardial infarction.
References
I. Topol EJ. Community hospital administration of intravenous tissue
plasminogen activator in acute myocardial infarction: improved tim-
ing, thrombolytic efficacyand ventricular function. J Am Coli Cardiol
1987;10:1173-7.
2. Satler LF. Levine S, Kent KM, et al. Aortic dissection masquerading
as acute myocardial infarction: implications of thrombolytic therapy
without cardiac catheterization. Am J Cardiol 1984;54:1134-5 .
3. Rogers Wl, Goode WP lr, Mantle lA , et al. Return of left ventricular
function after reperfusion in patients with myocardial infarction: im-
portance of subtotal stenosis or intact collaterals. Circulation
1984;69:338-49 .
4 . Braunwald E. Kloner RA. Myocardial reperfusion: a double-edged
sword? 1 Clin Invest 1985;76:171 3-9.
5. Broken R. Tillisch J. Schwaiger M, et al. Regional perfusion. glucose
metabolism and wall motion in patients with chronic electrocardio-
graphic Q-wave infarctions: evidence for persistence of viable tissue
in some infarct regions of positron emission tomography. Circulation
1986:73:951- 63.
6. Eisenberg 10 , Sobel BE. Gellman EM. Differentiation of ischemic
from non-ischemic cardiomyopathy with positron emission tomogra-
phy. Am 1 Cardiol 1987;59:1410- 6.
7. Rackley CEoRussell. RO Jr, Rogers wr. Mantle JA, McDaniel HG,
Papapietro SE. Clinical experience with glucose-insulin-potassium in
acute myocardial infarction. Am Heart 1 1981;102:1038- 49.
8. Satler LF. Green CEo Kent KM. Pallas RS. Pearle DL. Rackley CEo
Metabolic support during coronary reperfusion. Am Heart J
1987;11 4:54- 8.
9. Satler LF. Pallas RS. Bonn OB. ct al. Assessment of the residual
coronary arterial stenosis alier thrombolytic therapy during acute myo-
cardial infarction. Am 1 Cardiol 1987;59:1231 -3.
10. Satler LF. Rackley CE, Green CE, et al. Ischemia during angioplasty
after streptokinase: a marker of myocardial salvage. Am 1 Cardiol
1985;56:749-52.
II . Satler LF. Kent KM. FOil LM. et al. The assessment of contractile
reserve after thrombolytic therapy for acute myocardial infarction. Am
Heart J 1986:111:821-5 .
12. Satler LF. Green CE, McNamara NM, et al. Late angiographic follow-
up after successful thrombolysis and angioplasty. Am J Cardiol 1987:60:
210-3 .
13. Pratt CM. Slymen DJ. Wierman AM, et al. Asymptomatic telephone
ECG transmission as an outpatient surveillance system of ventricular
arrhythmias: relationship to quantitative ambulatory ECG recordings.
Am Heart J 1987:113:1-7 .
14. Sobel BE. Field LE, Robison AK. Fox KAA. Sarnoff 51. Coronary
thrombolysis with facilitated absorption of intramuscularly injected
tissue-type plasminogen activator. Proc Nail Acad Sci USA
1985:82:4258-62 .
